Financial Performance - For the fiscal year ending December 31, 2023, the company's revenue was approximately HKD 124.3 million, a decrease of about 59% compared to HKD 301.3 million in 2022[7] - The company reported a loss attributable to equity holders of approximately HKD 19.1 million for the year, compared to a profit of HKD 4.0 million in 2022[7] - The company incurred operating losses of HKD 20.7 million for the year, compared to an operating profit of HKD 4.2 million in 2022[9] - The company’s basic and diluted loss per share was HKD 1.29, compared to earnings of HKD 0.27 per share in the previous year[9] - The revenue from the main products for the year ended December 31, 2023, was HKD 124,255 thousand, a decrease of 58.8% compared to HKD 301,318 thousand in 2022[21] - The revenue from health-related products dropped significantly to HKD 18,209 thousand in 2023 from HKD 87,876 thousand in 2022, representing a decline of 79.2%[21] - The company's revenue for the year was approximately HKD 124,255,000, a significant decrease of about 59% compared to approximately HKD 301,318,000 for the year ended December 31, 2022[46] - The gross profit for the year was approximately HKD 15,294,000, down from approximately HKD 69,669,000 in 2022, reflecting a significant decline due to reduced income from health-related products[57] - The total sales cost for the year was approximately HKD 108,961,000, a reduction of about 53% from approximately HKD 231,649,000 in 2022[56] Assets and Liabilities - The total assets as of December 31, 2023, amounted to HKD 116.1 million, down from HKD 153.8 million in 2022[11] - The total equity attributable to equity holders was HKD 92.3 million, a decrease from HKD 111.2 million in the previous year[11] - The company’s cash and cash equivalents were HKD 47.4 million, down from HKD 85.7 million in 2022[11] - The company’s total liabilities decreased to HKD 27.4 million from HKD 44.4 million in the previous year[11] - The accounts receivable decreased to HKD 7,944,000 from HKD 10,031,000 in 2022[11] - Accounts payable decreased to HKD 19,034,000 from HKD 34,464,000 in 2022[44] Dividends - The board of directors did not recommend the declaration of any final dividend for the year[7] - The company did not declare any dividends for the current year, consistent with the previous year[36] Governance and Compliance - The company has adopted the principles and code provisions of the Corporate Governance Code as per GEM Listing Rules Appendix C1, ensuring high standards of corporate governance to protect shareholder interests[75] - The company has complied with all code provisions of the Corporate Governance Code in effect during the year[76] - The Audit Committee, established on January 20, 2014, consists of three independent non-executive directors, with Ms. Xu Huimin serving as the chairperson, ensuring proper oversight of the annual audited performance[77] - The auditors, PwC, confirmed that the figures in the preliminary performance announcement align with the audited consolidated financial statements for the year ending December 31, 2023[78] Future Outlook - The company plans to explore product diversification and seek new suppliers and customers to address market challenges[53] - The company continues to explore opportunities in the health-related product market despite the decline in demand due to the easing of the COVID-19 pandemic[50] Legal Matters - The company is actively defending against the claims made by the Securities and Futures Commission, with legal proceedings ongoing as of the announcement date[74] Meeting and Shareholder Information - The company's annual general meeting is scheduled for June 18, 2024, with a notice to be published in accordance with GEM Listing Rules[79] - Share transfer registration will be suspended from June 13 to June 18, 2024, to determine voting rights at the annual general meeting[81] - The board of directors includes four executive directors and five independent non-executive directors, with several members currently suspended from their positions[82]
圆美光电(08311) - 2023 - 年度业绩